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Abstract
Background: Recent advances in proteomics have shed light to discover serum proteins or peptides as biomarkers for
tracking the progression of diabetes as well as understanding molecular mechanisms of the disease.
Results: In this work, human serum of non-diabetic and diabetic cohorts was analyzed by proteomic approach. To analyze
total 1377 high-confident serum-proteins, we developed a computing strategy called localized statistics of protein
abundance distribution (LSPAD) to calculate a significant bias of a particular protein-abundance between these two cohorts.
As a result, 68 proteins were found significantly over-represented in the diabetic serum (p,0.01). In addition, a pathway-
associated analysis was developed to obtain the overall pathway bias associated with type 2 diabetes, from which the
significant over-representation of complement system associated with type 2 diabetes was uncovered. Moreover, an up-
stream activator of complement pathway, ficolin-3, was observed over-represented in the serum of type 2 diabetic patients,
which was further validated with statistic significance (p=0.012) with more clinical samples.
Conclusions: The developed LSPAD approach is well fit for analyzing proteomic data derived from biological complex
systems such as plasma proteome. With LSPAD, we disclosed the comprehensive distribution of the proteins associated
with diabetes in different abundance levels and the involvement of ficolin-related complement activation in diabetes.
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Introduction
Diabetes mellitus (DM) is one of the most common metabolic
disorders in the world, in which more than 90% are grouped to
type 2 diabetes mellitus (T2DM) [1]. Given the predicted
explosion in the number of T2DM cases worldwide [2], the
biomedical researchers face much stronger challenges, particularly
on understanding the pathogenesis of disease and discovering
biomarkers for tracking the disease process.
T2DM is characterized by abnormal glucose homeostasis
leading to hyperglycemia, and the serum glucose has been used
as a golden standard for diabetes diagnosis. However, T2DM is a
kind of disease involving defects of multiple organs, which cannot
be distinguished through the measurement of the serum-glucose
level. In addition, T2DM is a multiple-stage disease, which usually
covers several decades from impaired plasma glucose to various
complications. The serum-glucose level only reflects the conse-
quence of multiple physiological disorders in the given stage.
Therefore, many efforts have been made to identify genetic and
protein markers to reveal the molecular/cellular details or
progression of diabetes [3–9]. The genetic defects certainly render
more probability to diabetes. On the other hand, the protein
markers can track real-time status of diabetes. It has been found
there are changes in the protein abundances of serum in diabetes
progression [10,11]. For instance, a number of studies suggest that
the elevated circulating inflammatory biomolecules such as C-
reactive protein and serum amyloid A can be used for predicting
the development of T2DM [12–15]. However, since the
traditional strategy of diabetic diagnosis only relies on the
individual molecules as the biomarkers, the sensitivity and
accuracy of the biomarkers might be fluctuated due to ethnic or
personal variance [16–18]. Proteomic technology might provide
the new solutions for solving this problem, which can identify large
set of the proteins in cells or tissues through high-throughput
methods, and provide a globe view of the protein changes
associated with diabetes.
It is well known that serum severs the optimal resource for
discovery of disease biomarkers. Up to now, a few proteomic
analyses of serum related to diabetes have been reported. For
example, Dayal B et al. used the protein-chip to identify the high-
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3224density lipoproteins apoA-I and apoA-II and their glycosylated
products in patients with diabetes and cardiovascular disease [19].
Zhang et al. found that the protease inhibitors including clade A
and C, alpha 2-macroglobulin, fibrinogen, and the proteins
involved in the classical complement pathway such as complement
C3, and C4 exhibited the higher expression-levels in insulin
resistance/type-2 diabetes [20]. Bergsten et al. analyzed the serum
proteins in T2DM by SELDI-TOF-MS and peptide-mass
fingerprinting (PMF), and found the expression levels of
apolipoprotein, complement C3 and transthyretin were over-
represented, whereas albumin and transferrin were under-
represented in T2DM [21].
However, none of these above works provided the real globe
view for the protein profile of the diabetic serum, since the
proteomic analysis of serum is a formidable challenge for its huge
complexity and dynamic range [11,22]. Recent advances in serum
sample preparation such as a depletion of high abundance proteins
can be coupled to 1D or 2D-LC-MS/MS analysis, which have
provided the new ways for large-scale serum proteomic analysis
[23–25]. However, the step of the depletion of the high abundance
proteins might cause some artifacts. In the present study, we used a
label-free proteomic method with LC-MS/MS to investigate the
protein profiling between the non-diabetic and diabetic serum
without removing the high abundant proteins. After analyzing the
proteomics data according to the stringent criteria, a total of 3,010
proteins and 3,224 proteins were identified from the non-diabetic
and diabetic serum, respectively. In-depth bioinformatic analysis
was employed for these differential proteins between the non-
diabetic and diabetic serum.
Results
Selection of non-diabetic subjects and diabetic patients
Previous studies observed that T2DM might occurred at a
greater frequency in adults who are younger than 65 years,
suggesting that people who are old than 65 without diabetes
mellitus usually do not anticipate the genetic susceptibility [26].
Therefore, we set age criteria for sample cohort that an adult in
the present study must be old than 65 years (Non-diabetic subjects:
age 67.661.67 years; type 2 diabetic patients: age 6761.71 years)
in order to reduce the genetic effects related to T2DM between
non-diabetic and diabetic cohort. Furthermore, the careful
selection of samples was performed based on the clinical
parameters of non-diabetic and diabetic cohorts. Supplementary
Table S1 summarized the clinical parameters of the selected non-
diabetic subjects and diabetic patients, in which type 2 diabetic
patients group had higher FPG, PG2H, WT, BMI, HOMA,
HbA1c and C-peptide compared with control. To reduce the
individual variance of serum proteins within the cohort, we pooled
all the serum of each cohort for proteomic analysis, respectively.
Semi-quantitative proteomic identification in non-
diabetic and diabetic serum
We analyzed differential protein profile in two cohorts using
shotgun proteomics and label-free quantitative strategy. In order to
reduce sample complexity, proteins in non-diabetic and diabetic
serum were first separated on SDS-PAGE gel and the gel bands were
excised and subjected to in-gel tryptic digestion, respectively
(Figure 1A). The proteins were identified with criteria corresponding
to an estimated false dicovery rate of 2.5%. After combining the MS/
MS data generated from our experiment, we were able to assign
1,212,256 MS/MS spectra to 150,881 peptide counts, leading to
identification of 5,882 unique peptides corresponding to 3,010
protein groups in non-diabetic serum, and 1,211,006 MS/MS
spectra to 189,792 peptide counts, resulting in 5,960 unique peptides
corresponding to 3,224 protein groups in diabetic serum (all these
identified protein groups are called proteins in the text below for
clarity). Supplementary Figure S1 showed the quite similar
distributions of the identified peptides and proteins between non-
diabetic and diabetic serum, indicating non-bias of the identified
MS/MS spectra between non-diabetic and diabetic serum.
Among the identified 3,010 proteins in non-diabetic serum and
3,224 proteins in diabetic serum, 942 (30.30%) and 1,046
(32.44%) proteins were selected respectively under the condition
that each identified protein contained at least two peptide spectral
Figure 1. Overview of Idnetitication of proteins in non-diabetic
and diabetic serum. (A) Scheme of label-free strategy to differential
protein identification in non-diabetic and diabetic serum. Pooled serum
samples from five non-diabetic and five diabetic sera were separated
respectively by gel electrophoresis. Each gel lane was divided into 42
regions and each section was processed for mass spectrometry. (B)
1377 proteins were identified by at-least two peptide spectral counts in
either serum. 888 overlapped proteins were identified both in non-
diabetic and diabetic serum, whereas 223 proteins were identified
uniquely from the non-diabetic serum and 266 proteins were found
uniquely from the diabetic serum.
doi:10.1371/journal.pone.0003224.g001
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more stringent filter, resulting the false discovery rate of 1.6%.
There were 888 identified proteins overlapped in non-diabetic and
diabetic serum, whereas 223 proteins were identified uniquely
from the non-diabetic serum and 266 proteins were found
uniquely from the diabetic serum (Figure 1B, Supplementary
Table S2).
Localized statistics of protein abundance distribution
(LSPAD)
Since the peptide-spectral-count distributions of identified 1377
serum-proteins were widely spread out to the range of 10
5
(Supplementary Table S2), we developed M-A plotting referring to
microarray analysis in order to display a relative protein-
abundance distribution of each protein. First, for each protein,
X1 representing its peptide spectral counts in diabetic serum was
transformed into Y1 with formula f(X1)=log2(X1+1) as diabetic
protein abundance, while the X2 in non-diabetic serum was
transformed into Y2 with the same formula as a non-diabetic
protein abundance. Then, we defined ‘‘M’’ as differential protein
abundance between diabetic and non-diabetic serum by the
formula of Y12Y2, and ‘‘A’’ as an average protein abundance by
the formula of (Y1+Y2)/2. Based on these formulas, total 1377
proteins were plotted as a scatter chart, in which the values of M
were distributed on the Y-axis, and the values of A were
distributed on the X-axis (Figure 2A).
This scatter chart showed that the log2-ratio-range of the
differential protein-abundances between non-diabetic and diabetic
serum was considerably decreased along M-axis when the protein-
abundances were increased along A-axis (Figure 2A). These
observations indicated that the abundance ratio based on peptide
spectral counts cannot be simply used as indicators for differential
significance between diabetic and non-diabetic serum. For
example, the significance of 2-fold change from 2 to 1 peptide
spectral counts is not equal to the significance of 2-fold change
from 20000 to 10000. In addition, we realized that the protein-
distribution profiles at the low, middle and high level of protein
abundance, respectively, were considerably different (Figure 2B),
suggesting significance-calculation of particular differential pro-
teins should be localized to a certain range of related abundance
level. Therefore, we developed a computing method called
Localized Statistics of Protein Abundance Distribution (LSPAD)
to evaluate the statistical significance of protein-abundance bias
between diabetic and non-diabetic serum, by which the differentia
significance of a particular protein should be calculated through its
local protein-abundance distribution-window rather than through
whole distribution range from the lowest to highest protein-
abundances. Since the whole distribution range of protein
abundances could be generally subdivided into three parts (high,
middle and low protein-abundances, see Figure 2 and Supple-
mentary Table S2), we postulated a width of the local window for
statistics as 33%, i.e. only neighbored proteins with A value
located within the 33% A-axis around a particular protein should
be used for calculation.
In detail, for a particular protein, all the average peptide
spectral counts of neighbored proteins whose A value were within
the 33% abundance-window of the target protein were calculated
as a background to evaluate the statistical significance (p value) of
over-representation or under-representation of the target protein
by performing fisher’s exact test on a following four-fold table:
Figure 2. Quantitative strategy of proteins in non-diabetic and diabetic serum. (A) M-A plotting of 1377 identified proteins. ‘‘M’’ was
defined as differential protein abundance ratios of each protein between diabetic and non-diabetic serum, and ‘‘A’’ was defined as protein-
abundance of each protein. In addition, ret dots represented statistically significant over-represented proteins in diabetic serum, green dots
represented statistically significant under-represented proteins in diabetic serum, and grey dots were proteins without statistically-significant change
in diabetic serum and non-diabetic serum. (B) The distribution profiles of 1377 identified proteins (black line), identified proteins with M less than 5
(red line), between 5 and 10 (green line), and more than 10 (blue line).
doi:10.1371/journal.pone.0003224.g002
D ND
Peptide spectral counts of a target protein X1 X2
Sum of counts of all the other proteins in the window S1 S2
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transformed into p9 in order to evaluate the bias of each protein-
abundance between diabetic and non-diabetic serum.
The formula of linear transformation is p0~
p=2,sgn~1
1{p=2,sgn~{1
 
:
(sgn=1 indicates that a protein is over-represented in diabetic
sample, and sgn=21 indicates that a protein is over-represented
in non-diabetic sample)
To evaluate the reliability of LSPAD, we carried out the MA-
plotting analyses to two duplicates of diabetic serum sample. First,
the duplicates of one pooled diabetic-serum sample were separated
by SDS-PAGE, and the entire gel was cut into 12 gel slices for LC-
MS/MS analysis (Supplementary Figure S2A). The results showed
the consistent proteomic data from these two duplicates (Supple-
mentary Figure S2B–E). Then these data were subjected to
LSPAD analysis. The result showed few protein-variants by
comparing the protein-abundances between two duplicates of one
pooled diabetic-serum sample with LSPAD method (Supplemen-
tary Figure S3A). Furthermore, we analyzed the expression-
differentiation significance of one diabetic-serum duplicate versus
a non-diabetic serum (Supplementary Figure S3B), and the other
diabetic-serum duplicate versus the same non-diabetic serum
(Supplementary Figure S3C). The Supplementary Figure S3D
showed the high correlation coefficient of the M values between
the significantly differential proteins in Supplementary Figure S3B
and S3C. Taken together, these results indicate that this LSPAD
method is reliable for exploring the differentiation of the protein
abundances between non-disease and disease serum.
Accordingly, after 42 gel bands were analyzed in diabetic and
non-diabetic serum respectively (Figure 1), 1377 identified proteins
were analyzed by LSPAD approach. All the significant abun-
dance-biases of 1377 proteins were calculated (Supplementary
Table S2). Furthermore, we marked the proteins with p9,0.01 in
red color as the significantly over-represented in diabetic serum,
the proteins with p9.0.99 in green color as the significantly under-
represented in diabetic serum, and the non-significantly differen-
tial proteins in grey color (Figure 2).
The 68 significant over-represented proteins in diabetic serum
were listed in Table 1. Many known risk factors of diabetes such as C-
reactive protein, serum amyloid A and haptoglobin were over-
represented in diabetic serum, in agreement with the observations by
traditional approaches based on the analysis of individual proteins
[27]. In addition, a number of other factors including the novel
proteins associated with diabetes were detected by this large-scale
survey (Table 1). On the other hand, 74 proteins were found under-
represented in diabetic serum (Supplementary TableS2). As far as we
know, some studies reported that Keratin and IgG were associated
with diabetes [28,29]. In addition, a lot of keratins were also involved
in the pathway of cell communication (Supplementary Figure S4) in
our results. According to our pathway-associated differential
significance analysis, we found keratin associated pathway were
significantly overall bias with diabetic serum, which might not result
from the bias of sample preparation.
Pathway-associated differential significance analysis
To further reveal the significant bias of the protein abundances at
the level of biological pathways in diabetic serum, we mapped those
1377 proteins into KEGG pathways [30]. Total 1377 identified
proteins in the present study involved in 147 related pathways
(Supplementary Table S3). Then, we calculated these proteins with
theirp-valuesatthepathwaylevelinordertodiscoveroverallbiasof
pathways associated with diabetic-serum. The calculation proce-
dure was as follows: Supposing all the proteins are non-differential
expressed and independent of each other, their p-values, p, should
follow a uniform distribution between[0,1]. Thus, z=qnorm(p),
should follow a standard normal distribution (here qnorm is normal
inverse distribution function). After the normal inverse transforma-
tion of pi to zi, the summarized Z score for a certain pathway j was
generated by the formula, Zj~
P
nj
i~1
zixi
ﬃﬃﬃ nj
p .H e r enj was the number of
the proteins involved in the pathway j in our experiments, and
ix={ixi} denoted the index of these proteins. Because the proteins
involved in the pathway j were supposed to be non-differential
expressed and independent of each other, the summarized score for
pathway j, Zj, should also follow a standard normal distribution. In
our case, for pathway j, the following hypothesis test was performed:
H0: Zj follows the standard normal distribution, indicating that the
pathway is not un-biased in diabetic serum.
H1: Zj doesn’t follow the standard normal distribution, indicating
that the pathway is over-represented or under-represented in
diabetic serum
P value for pathway j, Pj, was transformed from Zj by a normal
cumulative function, p=pnorm(z). Under a statistic significance
threshold a, an over-represented pathway in diabetic serum was
identified with Pjva=2 and under-represented pathway was
identified with Pjv1{a=2. If the P value is less than 0.01, it
indicates that this pathway is significantly overall overrepresented
in diabetic serum compared with non-diabetic serum. If the P
value is more than 0.99, it means that this pathway is significantly
overall overrepresented in non-diabetic serum.
Among the 147 pathways, we selected 18 pathways, in which each
pathway should have at least5identified proteinsaswell asmorethan
10% coverage of all the pathway-proteins in the database, to evaluate
the pathway-bias between non-diabetic and diabetic serum. All the
values of the protein-abundance biases in these 18 pathways were
presented in Supplementary Figure S4. Particularly, the pathways of
complement system, PPAR system, cell communication and
Alzheimer’s disease showed the significantly overall over-representa-
tion in diabetes serum (p,0.01), while insulin signaling, coagulation
cascade, focal adhesion and long-term pathways presented signifi-
cantly overall bias in non-diabetic serum (p.0.99) (Figure 3).
These significant differential pathways could be subdivided into
two major categories: one had many significant-differential compo-
nents in one pathway, and the other had a few highly significant-
differential components in one pathway. For example, on the PPAR
pathway, three apolipoproteins were allover-represented significantly
in diabetic serum (Figure 4A). In Alzheimer’s disease pathway, the
apoliprotein E over-presentation also contributed the overall bias of
this pathway to diabetic serum. Therefore, apolipoproteins could be
considered as a kind of the important biomarkers associated with
diabetes. As previous reports, many apolipoproteins were involved in
lipid metabolism [31–43]. These proteins were further selected to
show their abundance biases between non-diabetic and diabetic
serum.Asshown inFigure4B,8proteinsincluding apolipoprotein A-
I, AII, C-II and C-III were significantly over-represented in diabetic
serum, whereas 6 proteins were significantly under-represented in
diabetic serum, which covered some regulatory factors such as
paraoxonase 1 (PON1) in lipid metabolism.
Over-representation of ficolin-related complement
pathway in diabetic serum
Our results showed that 12 proteins associated with comple-
ment system were significantly over-represented in diabetic serum
Diabetes Serum Proteome
PLoS ONE | www.plosone.org 4 September 2008 | Volume 3 | Issue 9 | e3224Table 1. Characterization of proteins significantly over-represented in diabetic serum compared to non-diabetic serum based on
LSPAD method. (P,0.01).
IPI ID Protein name
Diabetic peptide
spectral count
Non-diabetic peptide
spectral count P value
IPI00022434 ALB protein 61457 47082 4.09E-91
IPI00514824 Complement component C4B 875 183 1.44E-80
IPI00555805 Complement component 4A 3896 2109 1.63E-69
IPI00032258 Complement C4 precursor 3846 2077 3.06E-69
IPI00453459 Complement Component 4B preproprotein 3933 2141 9.77E-69
IPI00418163 C4B1 3811 2077 2.48E-66
IPI00384697 ALB protein 47105 37323 6.64E-37
IPI00556148 Complement factor H 2732 1691 1.30E-30
IPI00465313 Alpha 2 macroglobulin variant 17016 13013 7.50E-26
IPI00478003 Alpha-2-macroglobulin precursor 17344 13335 3.06E-24
IPI00385264 Ig mu heavy chain disease protein 1614 880 4.42E-23
IPI00164623 Complement C3 precursor 9754 7267 8.64E-22
IPI00479708 Immunoglobulin heavy constant mu (IGHM) 2007 1204 1.02E-21
IPI00549273 Immunoglobulin heavy constant mu (IGHM) 1995 1190 3.09E-21
IPI00019943 Afamin precursor 553 221 1.57E-20
IPI00479169 65 kDa protein 1932 1181 2.35E-18
IPI00022488 Hemopexin precursor 1952 1268 2.99E-14
IPI00426051 Hypothetical protein DKFZp686C15213 5203 3835 6.18E-14
IPI00021727 C4b-binding protein alpha chain precursor 638 321 1.01E-13
IPI00478493 Haptoglobin precursor 4214 3100 7.28E-12
IPI00550991 Alpha-1-antichymotrypsin precursor 1088 628 2.99E-11
IPI00019591 Splice Isoform 1 of Complement factor B precursor 1183 696 4.42E-11
IPI00021842 Apolipoprotein E precursor 394 181 3.28E-10
IPI00019399 Serum amyloid A-4 protein precursor 143 43 9.21E-10
IPI00021857 Apolipoprotein C-III precursor 144 49 3.87E-08
IPI00022392 Complement C1q subcomponent, A chain precursor 103 30 1.25E-07
IPI00021841 Apolipoprotein A-I precursor 4069 3112 2.14E-07
IPI00010865 Casein kinase II beta subunit 23 0 2.70E-07
IPI00396929 PREDICTED: similar to immunoglobulin M chain 165 68 1.55E-06
IPI00410714 Alpha 2 globin variant 433 244 3.33E-06
IPI00163446 The Human Immunoglobulin Heavy Diversity (IGHD) 134 53 4.03E-06
IPI00171834 Keratin, type I cytoskeletal 19 140 57 1.29E-05
IPI00399007 Hypothetical protein DKFZp686I04196 5114 4039 1.41E-05
IPI00003590 Quiescin Q6 15 0 4.53E-05
IPI00022389 Splice Isoform 1 of C-reactive protein precursor 15 0 4.53E-05
IPI00015309 Keratin, type I cytoskeletal 12 89 33 7.63E-05
IPI00290077 Keratin, type I cytoskeletal 15 142 62 8.21E-05
IPI00217963 Keratin, type I cytoskeletal 16 223 117 0.000146102
IPI00418422 The Human Immunoglobulin Heavy Diversity (IGHD) 69 23 0.000152193
IPI00423461 Hypothetical protein DKFZp686C02220 828 548 0.000223242
IPI00450768 Keratin, type I cytoskeletal 17 147 69 0.000275352
IPI00011261 Complement component C8 gamma chain precursor 266 152 0.000391696
IPI00556567 Ficolin-3 protein 80 33 0.000819734
IPI00441196 Hypothetical protein 3090 2450 0.000949718
IPI00386839 Amyloid lambda 6 light chain variable region SAR 180 98 0.001229635
IPI00017601 Ceruloplasmin precursor 2260 1816 0.001476612
IPI00383953 VH4 heavy chain variable region precursor 132 64 0.001483067
IPI00009866 Keratin, type I cytoskeletal 13 107 52 0.001918932
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PLoS ONE | www.plosone.org 5 September 2008 | Volume 3 | Issue 9 | e3224Figure 3. The overall bias analysis of selected pathways found in non-diabetic and diabetic serum. Proteins identified in non-diabetic
and diabetic serum were mapped to known pathways using KEGG. The p value of each pathway was digitized to the length of the bar diagram.
doi:10.1371/journal.pone.0003224.g003
IPI ID Protein name
Diabetic peptide
spectral count
Non-diabetic peptide
spectral count P value
IPI00470798 Hypothetical protein DKFZp686E23209 4508 3647 0.002098573
IPI00017530 Ficolin-2 precursor 9 0 0.002266054
IPI00021854 Apolipoprotein A-II precursor 853 582 0.002359293
IPI00004550 Hypothetical protein FLJ20261 96 45 0.00238822
IPI00011252 Complement component C8 alpha chain precursor 81 36 0.002415224
IPI00293898 Hepatocellular carcinoma associated protein TB6 19 4 0.002727717
IPI00384444 Keratin, type I cytoskeletal 14 207 120 0.003122976
IPI00021856 Apolipoprotein C-II precursor 32 11 0.00418406
IPI00219806 S100 calcium-binding protein A7 8 0 0.004391148
IPI00446354 Hypothetical protein FLJ41805 8 0 0.004391148
IPI00479762 115 kDa protein 8 0 0.004391148
IPI00022446 Platelet factor 4 precursor 82 39 0.00501026
IPI00300725 Keratin, type II cytoskeletal 6A 158 90 0.005161139
IPI00242956 Fc fragment of IgG binding protein 24 8 0.006549075
IPI00384401 Myosin-reactive immunoglobulin kappa chain variable region25 8 0.006595492
IPI00293665 Keratin, type II cytoskeletal 6B 141 79 0.00706398
IPI00299145 Keratin, type II cytoskeletal 6E 144 83 0.007903541
IPI00383603 Anti-thyroglobulin light chain variable region 7 0 0.008537501
IPI00452748 Serum amyloid A protein precursor 7 0 0.008537501
IPI00021304 Keratin, type II cytoskeletal 2 epidermal 810 575 0.009876282
doi:10.1371/journal.pone.0003224.t001
Table 1. cont.
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activated through three different ways, including lectin, classical
and alternative pathways (Figure 5B) [44,45]. The present work
showed that two trigger factors of lectin-complement activation,
ficolin-2 and ficolin-3, were both over-represented significantly in
the diabetic serum (Table 1), while the ficolin-3 was detected with
much higher abundance than ficolin-2. Another kind of lectin
related to complement initiation, mannose biding lectins (MBL),
was not detected. These results indicate that ficolin-3 might be the
major trigger of lectin-complement activation in diabetic patients.
Validation of ficolin-3 related complement activation in
diabetic serum
When the complement system is activated, the complement C3
is cleaved to C3a and C3b, which is the common and crucial step
in all complement activation pathways (as shown in Figure 5B,
[46]). To validate the level of C3 and its activation, Western
blotting for C3, corresponding fragment C3a and C3b were
performed in the non-diabetic and diabetic serum. It was
confirmed that these proteins were over-represented in diabetic
serum (Figure 6).
Figure 4. The identified proteins and abundance biases in specific pathways. (A)PPAR system, (B) Apolipoproteins associated Lipid
metabolism. The p value of identified protein was digitized to the length of the bar in each pathway.
doi:10.1371/journal.pone.0003224.g004
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PLoS ONE | www.plosone.org 7 September 2008 | Volume 3 | Issue 9 | e3224Figure 5. Overview of proteins associated with complement system. (A) The identified proteins and the abundance biases in complement
system. The p value of identified protein was digitized to the length of the bar in each pathway. (B) The three activation pathways of complement
system: the classical, mannose-binding lectin, and alternative pathways. The three pathways converge at the point of cleavage of C3. Therefore, the
C3 cleavage is the crucial step in activation of the three complement pathway. Molecules of C3 are cleaved to C3a and C3b by the C3 convertase. C3b
binds covalently around the site of complement activation. Some of this C3b binds to the C4b and C3b in the convertase enzymes of the classical and
alternative pathways, respectively, forming C5 convertase enzymes. This C3b acts as an acceptor site for C5, which is cleaved to form the
anaphylatoxin C5a and C5b, which initiates the formation of the membrane-attack complex. Excitedly, ficolin-3 is a biologically active protein of the
lectin-complement activation in association with MBL-associated serine protease (MASP). In this figure, significantly up-regulated proteins in diabetic
serum were denoted with red color, slightly up-regulated proteins in diabetic serum were denoted with light red color, significantly up-regulated
proteins in non-diabetic serum were denoted with blue color, and slightly up-regulated proteins in non-diabetic serum were denoted with light blue
color. Not identified proteins or the fragment of the complement component were denoted with light grey color.
doi:10.1371/journal.pone.0003224.g005
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complement activation [46,47]. Our studies identified 33 and 80
spectral peptide counts of ficolin-3 from non-diabetic and diabetic
serum, respectively (Table 1). Among these detected peptides, two
particular peptides (VVLLPSCPGAPGSPGEK and YAV-
SEAAAHK) were detected exclusively from diabetic serum
(Figure 7A and 7B). Taken together, these findings indicate that
ficolin-3 in diabetic serum are over-represented in diabetic serum.
We further confirmed this observation by Western blotting
(Figure 6).
In order to evaluate the correlation of ficolin-3 with diabetes,
the protein-abundance of ficolin-3 was validated by Western
blotting in additional clinical sera from 24 non-diabetic subjects
and 24 diabetic patients (Supplementary Table S4). As shown in
Figure 7C and Supplementary Figure S5, the level of serum
ficolin-3 was 0.9060.43 in non-diabetic sera and 1.4360.87 in
diabetic sera (p=0.012). Taken together, these results suggest a
ficolin-3 related complement activation in diabetic serum.
Discussion
The strategy for analyzing the highly dynamical range of
protein abundances
In this study, LC-MS/MS coupled with a label-free quantitative
strategy was applied to analyze the differential serum-protein
abundance profile between non-diabetic and diabetic patients.
The label-free quantitation based on peptide-spectral counts offers
a high-coverage identification of proteins, and then gives a
comprehensive and rapid comparison to the differential proteins,
especially to the plasma proteins [48]. Since the distribution range
of the peptide-spectral counts of the serum-proteins was up to 10
5
(Supplementary Table S2), we applied M-A plotting method
referring to microarray data-analysis for analyzing the effects of
the different abundance-levels as well as the count-ratio of a
particular protein between non-diabetic and diabetic serum
(Figure 2A). From the Figure 2B, we realized that the lower the
abundance-level of the peptide-spectral counts, the higher the
deviation of the count-ratio. In this regard, we cannot fix a count-
ratio as a threshold covering low abundance-level to high
abundance-level for evaluating the bias of the protein abundance
of diabetic serum. In other words, the quantitative selection of
differentia proteins based on the ratio of the particular protein-
abundance, which is usually used in isotope-labeling proteomic
methods, seems not suitable in the peptide-spectral counts
quantification for the systems with the highly dynamic range of
protein-abundances, i.e. serum proteome.
Therefore, we developed a localized statistics of protein
abundance distribution (LSPAD) for identifying the over- or
under-represented proteins in diabetic serum. Based on this
method, we can calculate the significance of the peptide-spectral-
count bias for differentia proteins instead of using the count-ratio.
Furthermore, we defined an abundance-window of 33% around a
target protein as a localized background for calculating the
statistical significance, by which we can evaluate the significant
bias of a target protein-abundance compared to the abundance-
distribution range of its neighbored proteins rather than to the
abundance-distribution range of all identified proteins.
Involvement of lipid metabolism and inflammation in
type 2 diabetes
In this study, many individual proteins associated with T2DM
reported in previous studies were also identified. In the group of
apolipoproteins, for example, many components were over-
represented in diabetic serum including Apolipoprotein E, CII,
CIII and serum amyloid. Apo E content of postprandial TG-rich
lipoproteins in subjects with both T2DM and coronary artery
disease was increased [49]. Serum amyloid A, a major apoprotein
(45%) in high-density lipoproteins (HDL), was increased due to
inflammation [50]. Apolipoprotein C III (apo C III) plays a central
role in regulating plasma metabolism of triglyceride-rich lipopro-
tein (TRL). Previous studies suggested that apo C III might be an
independent risk factor for atherosclerotic diseases in Chinese type
2 diabetes [51]. On the other hand, we identified some under-
represented regulatory factors in lipid metabolism such as
paraoxonase1 (PON1). PON1 is an anti-inflammatory enzyme,
which participates in the prevention of low density lipoprotein
(LDL) oxidation [52,53]. Recently, Mackness et. al reported that
high C-reactive protein and low paraoxonase1 in diabetes might
be used as risk factors of coronary heart disease [53].
We also found certain proteins associated with acute-phase
response were over-represented in diabetic serum such as C-
reactive protein [54,55], serum amyloid A [56], haptoglobin [57],
a-1-acid glycoprotein [12], ceruloplasmin [58] and Von Will-
ebrand factor [59]. Recently, abundant scientific evidences
suggested the elevated circulating inflammatory markers such as
C-reactive protein could be used for the prediction of the
development of T2DM [12–15]. Moreover, C- reactive protein
was also as a biomarker for inflammation in uremia [60]. Studies
also showed that haptoglobin and C-reactive protein were
increased significantly in both diabetes and glucose intolerance
[57]. There has been an explosion of interests that the chronic low-
grade inflammation and the activation of the innate immune
system were closely involved in the pathogenesis of T2DM [61].
Complement activation in type2 diabetes
Cross-sectional study have demonstrated strong correlation
between complement C3 and insulin resistance, which showed
Figure 6. Western blot confirmation of the serum level of C3
(,187 kD), C3a (,9 kD), C3b (alpha’ chain, ,104 kD) and
Ficolin-3 (,34 kD). The Non-diabetic serum: the mixture of equal
amount of serum from five non-diabetic subjects in Table 1, Diabetic
serum: the mixture of equal amount of serum from five diabetic
patients in Table 1.
doi:10.1371/journal.pone.0003224.g006
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[47]. In the present study, the serum levels of C3 and its fragments
C3a were over-represented in diabetic serum by western blot
analysis, indicating the activation of complement system. Adipsin/
complement factor D is a serine protease that is secreted by
adipocytes into the bloodstream. Adipsin is deficient in several
animal models of obesity [62]. In our study, the expressing level of
adipsin was under-represented in diabetic serum. Lectin is also a
trigger for complement activation. This process begins due to the
binding of mannose-binding lectin (MBL) or ficolins with MBL-
associated serine protease-2 (MASP-2), and leads to the formation
of a C3 convertase [63–66]. Up to now, only a few evidences
showed that the increased level of MBL can provide prognostic
information in patients with T2DM [67]. In the present work,
MBL was not detected by mass spectrometry in serum, while both
ficolin-2 and ficolin-3 were detected over-represented in diabetic
serum. However, ficolin-2 was uniquely identified in diabetic
serum with only 9 spectral counts while ficolin-3 was detected with
much higher spectral counts. Therefore, it seems that ficolin-3
should be the major trigger and indicator of lectin-complement
activation. The Western-blotting of serum ficolin-3 with a lager
clinical population supports that serum ficolin-3 was significantly
over-represented and positively correlated with T2DM. Thus, we
argue that ficolin-3 triggers the lectin-complement pathway, which
might play an important role in the chronic low-grade inflamma-
tion and activation of the innate immune system associated with
T2DM.
In summary, the LSPAD approach developed in this present
work is well useful for analyzing proteomic data derived from
biological complex systems such as plasma proteome, by which we
disclosed the comprehensive distribution of the proteins associated
with diabetes among high, medium and low abundant proteins. In
addition, we found the involvement of the ficolin-related
complement system in type 2 diabetes.
Materials and Methods
Clinical sample collection and preparation
Ten male adults were selected for this investigation, including
five non-diabetic subjects (FPG 4.8260.21 mmol/L; PG2H
4.7861.54 mmol/L; BMI 21.6760.81 kg/m2; HbA1c
5.6860.54%; C-peptide 1.0960.25 ng/mL; and homeostasis
model assessment [HOMA] 1.0460.67), and five type 2 diabetic
patients (FPG 7.2662.73 mmol/L; PG2H 12.261.21 mmol/L;
Figure 7. MS/MS spectra of representative peptides from ficolin-3 and validation of ficolin-3 up-regulation in diabetic sera. (A)
VVLLPSCPGAPGSPGEK (B) YAVSEAAAHK (C) Western blot validation of the serum ficolin-3 level in the non-diabetic subjects and diabetic patients
(n=24, respectively) were conducted. N: non-diabetic serum; D: diabetic serum.
doi:10.1371/journal.pone.0003224.g007
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3.4461.31 ng/mL; HOMA 5.6763.96). The Homeostasis Model
Assessment (HOMA) for insulin resistance and b-cell function was
calculated from fasting plasma glucose and insulin concentrations.
Informed consent was obtained from each person in written
format and approved by Shanghai No. 6 People’s Hospital Review
Committee.
Immediately after collection, fasting blood samples were allowed
to clot at room temperature for four hours, and the serum were
collected and centrifugated at 3000 rpm/min for 15 min. Before
pooling the samples, the protein concentration of the serum
samples was determined by Bradford assay on a Microplate
Reader (Bio-Rad, Model 680). Five non-diabetic serum samples
were mixed as control-pool sample, and five diabetic serum
samples were also mixed as disease-pool sample. The two pooled
serum samples were diluted respectively to ,20 mg/mL with
100 mM phosphate buffer (pH 2.0, containing 5% ACN). Then,
the pooled serum samples were filtered through 0.22 mm filters
(Agilent technologies) by spinning at 10 000 g at 4uC for 30 min
and dialyzed to 100 mM phosphate buffer (pH 2.0, containing 5%
ACN).
Gel electrophoresis and In-Gel Digestion
The serum sample containing 1.8 mg proteins was reduced by
adding 2 mL of 1 M DTT to 10 mM and incubated at 37uC for
2.5 hours. The mixture then was added with 10 mL of 1 M IAA
and incubated for 40 min in darkness at room temperature. After
these treatments, the samples were subjected to SDS-PAGE on a
7.5–17.5% gradient gel. The gel lane stained with Coomassie Blue
was excised into 42 sections. Each excised section was cut into
approx. 1 mm
3 pieces and destained using 30% acetonitrile/70%
100 mM ammonium bicarbonate solution, followed by dehydra-
tion in 100% acetonitrile for 5 min. Gel pieces were placed under
vacuum centrifugation until completely dried. Each gel slice was
then incubated in a 50 mM ammonium bicarbonate solution
containing 10 ng/mL trypsin (Promega Biotech Co., Madison, WI,
USA.) overnight. Peptides were extracted with 0.1% TFA/80%
acetonitrile, dried by vacuum centrifugation, and stored at 280uC
for further analysis with mass spectrometry.
Label-free shotgun proteomic identification
Each gel slice containing peptides was dissolved in 60 mL 0.1%
formic acid, and then the half of this peptide-solution was loaded
into the RP column. RP-HPLC was performed using an Agilent
1100 Capillary system (Agilent technologies) with C18 column
(150 mm i.d., 100 mm length, Column technology Inc., Fremont,
CA). The pump flow rate was 1.6 mL/min. Mobile phase A was
0.1% formic acid in water, and mobile phase B was 0.1% formic
acid in acetonitrile. The tryptic peptide mixtures were eluted using
a gradient of 2–55% B over 135 min. The mass spectral data were
acquired on a LTQ linear ion trap mass spectrometer (Thermo,
San Jose, CA) equipped with an electrospray interface operated in
positive ion mode. The temperature of heated capillary was set at
170uC. A voltage of 3.0 kV applied to the ESI needle. Normalized
collision energy was 35.0. The number of ions stored in the ion
trap was regulated by the automatic gain control. Voltages across
the capillary and the quadrupole lenses were tuned by an
automated procedure to maximize the signal for the ion of
interest. The mass spectrometer was set as one full MS scan was
followed by ten MS/MS scans on the ten most intense ions from
the MS spectrum with the following Dynamic Exclusion
TM
settings: repeat count, 2, repeat duration, 0.5 min, exclusion
duration, 1.5 min.
Data analysis
All .dta files were created using Bioworks 3.1, with precursor
mass tolerance of 1.4 Da, threshold of 100, and minimum ion
count of 15. The acquired MS/MS spectra were searched against
the Human International Protein Index protein sequence database
(version 3.07, www.ebi.ac.uk/IPI) combined with sequences of real
protein and reverse sequences of proteins, by using the
TurboSEQUEST program in the BioWorks 3.1 software suite,
with a mass tolerance of 3.0 Da. All cysteine residues were
searched as carboxamidomethycystein (+57.02 Da). Up to one
internal cleavage sites were allowed for tryptic searches. All output
results were combined together using the in-house software named
BuildSummary to delete the redundant data. Searches were
conducted against the Human International Protein Index protein
sequence database to control the false discovery rate at 2.5% and
all spectral peptide count had a DCn score of at least 0.1. The
proteins identified by two or more peptide counts in either non-
diabetic or diabetic serum were used to the following bioinfor-
matics analysis.
Western bolt analysis of C3 and its fragments
Each of 100 mg non-diabetic and diabetic serum-proteins was
subjected to PAGE-gel electrophresis, and then proteins in the gel
were transferred to a nitrocellulose membrane. The membranes
were incubated first with the appropriate primary antibodies (C3b:
ab11871, C3a: ab11872, purchased from Abcam Ltd, Cambridge,
MA), respectively, and then incubated with HRP-conjugated
secondary antibodies for 45 min. The proteins were detected by
enhanced chemiluminescence (ECL-plus, Amersham Pharmacia
Biotech).
Validation of ficolin-3 over-representation in larger
samples
0.4 uL of each individual serum sample (non-diabetic and
diabetic subjects, n=24, respectively) diluted to 1/10 with 1.0 M
Tris (pH 6.8) buffer was separated by SDS-PAGE, and electro-
transferred to a nitrocellulose membrane (Whatman International
Ltd., England.). The membrane was blotted with a mouse
monoclonal antibody against human ficolin-3 (R&D Systems,
Inc., 1:500). Signal detection was achieved with ECL Plus
chemiluminescence system (Amersham Biosciences). Signal of
bands from Western blot were scanned with PDQUEST GS-710 a
flat-bed scanner and digitized with Gel-PRO Analyzer software
(Media Cybernetics, Inc., USA). To decrease the system
discrepancy, we used the serum of the same patient as the
reference. Relative level of serum ficolin-3 was calculated by the
proportion of density ratio of sample bands to that of the reference
band. These density ratios were used for statistical analyses of
serum ficolin-3 level between non-diabetic and diabetic subjects.
Statistical analysis
Data were expressed as means6standard deviation (SD) for
normally distributed values. Differences between groups for
normally distributed variables were tested using t-test (analysis of
variance). All calculations were performed with GraphPad Prism
software system (GraphPad San Diego, CA, USA) and SPSS13.0
statistical package (Statistical Software, Los Angeles, CA, USA). A
P value below 0.05 was considered statistically significant.
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